How I treat prolymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• T- and B-cell prolymphocytic leukemia (PLL) are rare, aggressive lymphoid malignancies.
• Specific oncogenes (TCL-1, MTCP-1, ATM) and TP53 mutations are implicated in T- and B-cell PLL, respectively.
• Despite biological insights, prognosis remains poor with limited curative options.

Purpose of the Study:

• To review current understanding and treatment strategies for T- and B-cell PLL.
• To highlight the impact of novel therapies like monoclonal antibodies.
• To explore the potential of allogeneic stem cell transplantation for curative treatment.

Main Methods:

• Review of recent studies on T- and B-cell PLL biology and treatment.
• Analysis of outcomes with alemtuzumab in T-cell PLL.
• Evaluation of rituximab-based chemo-immunotherapy in B-cell PLL.
• Consideration of stem cell transplantation approaches.

Main Results:

• First-line alemtuzumab yields >90% response rates and improved survival in T-cell PLL.
• Rituximab-based therapy is effective for fitter B-cell PLL patients.
• TP53-abnormal B-cell PLL may benefit from alemtuzumab-based therapy.
• Stem cell transplantation, particularly allogeneic, can consolidate remissions and offer cure.

Conclusions:

• Alemtuzumab represents a significant advancement in T-cell PLL treatment.
• Combination chemo-immunotherapy is a viable option for B-cell PLL.
• Allogeneic stem cell transplantation warrants further investigation for curative potential in both subtypes.